SEC Form 4 · accession 0001179110-18-009417
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dayton Misfeldt
Officer — Interim CEO · Director
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 7:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.12 | Jun 29, 2018 | A | 200,000 | A | — | Jun 29, 2028 | Common Stock | 200,000 | 200,000 | D |
| Stock Option(Right to Buy)F2 | $2.12 | Jun 29, 2018 | A | 25,000 | A | — | Jun 29, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests monthly over six (6) months from the date of grant subject to the optionee's continued service to the Company.
- F2The option shall vest and become exercisable in twelve (12)equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date.